■SARS-CoV-2，作为一种新的大流行性疾病，影响了世界。短链脂肪酸（SCFA），如乙酸，丙酸,丁酸是人体肠道菌群的主要代谢产物。SCFA在呼吸道合胞病毒引起的感染中显示出积极作用，腺病毒，流感,和鼻病毒。因此,这项研究旨在评估SARS-CoV-2患者与健康组相比的SCFAs浓度。
■这项研究是基于一项病例和对照研究设计的。从2021年9月至2021年10月，在大不里士，20名健康人作为对照组，20名冠状病毒病(COVID-19)实时聚合酶链反应检测呈阳性的住院患者被纳入研究，作为患者组。伊朗。从志愿者那里收集粪便标本，SCFA的分析是通过高效液相色谱系统进行的。
■健康组乙酸用量为67.88±23.09μmol/g,而COVID-19患者组为37.04±13.29μmol/g。因此,患者组的乙酸浓度显着（p<0.001）低于健康组。与病例组相比，对照组中丙酸和丁酸的含量较高；然而，该值无统计学意义(p>0.05)。
■这项研究表明，在COVID-19患者中，由肠道微生物群引起的代谢产物乙酸的浓度受到显着干扰。因此,未来研究中基于肠道微生物群代谢产物的治疗干预可能对COVID-19有效。
UNASSIGNED: SARS-CoV-2, as a new pandemic disease, affected the world. Short-chain fatty acids (SCFAs) such as acetic, propionic, and butyric acids are the main metabolites of human gut microbiota. The positive effects of SCFAs have been shown in infections caused by respiratory syncytial virus, adenovirus, influenza, and rhinovirus. Therefore, this study aimed to evaluate the concentration of SCFAs in patients with SARS-CoV-2 compared with the healthy group.
UNASSIGNED: This research was designed based on a
case and control study. Twenty healthy individuals as the control group and 20 persons admitted to the hospital with a positive test of coronavirus disease (COVID-19) real-time polymerase chain reaction were included in the study as the patient group from September 2021 to October 2021, in Tabriz, Iran. Stool specimens were collected from volunteers, and analysis of SCFAs was carried out by a high-performance liquid chromatography system.
UNASSIGNED: The amount of acetic acid in the healthy group was 67.88 ± 23.09 μmol/g, while in the group of patients with COVID-19 was 37.04 ± 13.29 μmol/g. Therefore, the concentration of acetic acid in the patient group was significantly (p < 0.001) lower than in the healthy group. Propionic and butyric acid were present in a higher amount in the control group compared with the
case group; however, this value was not statistically significant (p > 0.05).
UNASSIGNED: This study showed that the concentration of acetic acid as the metabolite caused by gut microbiota is significantly disturbed in patients with COVID-19. Therefore, therapeutic interventions based on gut microbiota metabolites in future research may be effective against COVID-19.
PDF(Pubmed)